Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Moschini M, Soria F, Susani M, Korn S, Briganti A, Rouprêt M, et al. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer. 2017;3(3):161-169.

Dutta A, Panja S, Virk RK, Kim JY, Zott R, Cremers S, et al. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. Eur Urol. 2017;72(4):499-506.

Lam HC, Baglini CV, Lope AL, Parkhitko AA, Liu H-, Alesi N, et al. p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. Cancer Res. 2017;77(12):3255-3267.

Xu B, Tallini G, Scognamiglio T, Roman BR, R Tuttle M, Ghossein RA. Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017;27(4):512-517.

Gong Q, Wang C, Zhang W, Iqbal J, Hu Y, Greiner TC, et al. Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data. Sci Rep. 2017;7(1):11301.

Petrova-Drus K, Hasserjian R, Pozdnyakova O, Dal Cin P, Mathew S, Margolskee E, et al. Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome. Leuk Lymphoma. 2017;58(3):569-577.

Salvatore SP, Chevalier JM, Kuo SF, Audia PF, Seshan SV. Kidney disease in patients with obesity: It is not always obesity-related glomerulopathy alone. Obes Res Clin Pract. 2017;11(5):597-606.

Nguyen GH, Olson LC, Magro CM. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. Ann Diagn Pathol. 2017;28:54-59.

Giulino-Roth L, van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, et al. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Mol Cancer Ther. 2017;16(9):1779-1790.

Gullett JC, Westblade LF, Green DA, Whittier S, Burd EM. The Brief Case: Too Beta To Be a "B". J Clin Microbiol. 2017;55(6):1604-1607.